Interim report January-September 2016
“All patients completed treatment in the pivotal Phase 3 opioid dependence trial and we are excited about receiving the study results. In parallel, we are preparing for submissions of marketing approval applications in Europe and the US during 2017.”Business highlights third quarter 2016 · Treatment of all patients completed in Phase 3 efficacy study of CAM2038 for treatment of opioid dependence. · First patient enrolled in a Phase 3 trial of CAM2038 in patients with chronic back pain. · Positive results received from Phase 2 study of CAM2029 in NET and acromegaly patients. ·